Research
Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1116 (Published 09 March 2015) Cite this as: BMJ 2015;350:h1116
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
- Data Supplement - Supplementary figures S1, S2, S3; supplementary tables S1 and S2; protocol for populating cohort B (stalled drugs); query to trialists about publication practice.
Related articles
- Editorial Published: 23 March 2006; BMJ 332 doi:10.1136/bmj.38797.635012.47
- EDITORIALS Published: 22 March 2006; BMJ doi:10.1136/bmj.38797.635012.47
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7202
- Research Published: 29 October 2013; BMJ 347 doi:10.1136/bmj.f6104
- Editorial Published: 26 June 2015; BMJ 350 doi:10.1136/bmj.h3444
- Research Published: 06 June 2018; BMJ 361 doi:10.1136/bmj.k2130
See more
- Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysisBMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188
- NHS to fund large trial of pre-exposure prophylaxis for HIV preventionBMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Alpha blockers for treatment of ureteric stones: systematic review and meta-analysisBMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112
- Sixty seconds on . . . solanezumabBMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389
Cited by...
- Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005
- Translational research and the U.S. federal elections
- Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
- The secret realm of phase I trials in healthy volunteers
- When drugs don't make it to market